There GlaxosmithKline is recalling remaining doses of a Flulaval quadrivalent flu vaccine due to efficacy issues. The letter was sent to approximately 1,000 customers across the United States, including wholesale distributors, pharmacies, government agencies and physicians. The recall affects about 1.7 million doses, of which more than the 99% of vaccines.
According to reports from the pharmaceutical company, the measure would not be related to vaccine safety problems and was adopted for precautionary purposes since a variability in the production process was detected that could attenuate its ability to induce an antibody response in the long run term. THE recalled vaccines they represent approximately 7% of the total 24 million doses of GlaxoSmithKline flu vaccine distributed in the United States this season.
